SynthesisFrontiers in medicine2025
Cardiovascular disease in idiopathic pulmonary fibrosis: a systematic review and meta-analysis of observational studies.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular (CV) comorbidities can affect drug tolerability and health outcomes in patients with idiopathic pulmonary fibrosis (IPF). This systematic review and meta-analysis aimed to quantify the magnitudes of association between IPF and both overall and specific categories of CV disease. Methods: The PRISMA guidelines and PICO model were followed. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese Biomedical Literature Service System (Sinomed) from inception to April 2025 for studies investigating CV disease in IPF patients. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled odds ratio (OR) for case-control/cross-sectional datasets and relative risk (RR) for cohort datasets were calculated using Review Manager 5.4. The Results: A total of 28 studies comprising 29 case-control/cross-sectional datasets and four cohort datasets were included, which indicated a positive association between IPF and CV disease (OR 2.44, 95% CI 1.84-3.24, Conclusion: Idiopathic pulmonary fibrosis is significantly associated with CV disease, emphasizing the urgent need for systematic screening and risk reduction strategies in IPF patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251013917, identifier CRD420251013917.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.